volume 41, issue 1, P71-75 2013
DOI: 10.1016/j.jcms.2012.10.018
View full text
Philipp Stockmann, Emeka Nkenke, Matthias Englbrecht, Tilo Schlittenbauer, Falk Wehrhan, Claudia Rauh, Matthias W. Beckmann, Peter A. Fasching, Thomas Kreusch, Andreas Mackensen, Bernd Wullich, Georg Schett, Bernd M. Spriewald

Abstract: The aetiology of anti-resorptive agent-induced osteonecrosis of the jaw (ARONJ) is still under debate. Clinical and genetic risk factors are currently being investigated to help understand its pathogenesis. This case-control study analysed a large number of cancer patients (n = 230) under therapy with intravenous bisphosphonates, half of which were diagnosed with ARONJ. Multiple myeloma, greater patient age and the use of more than one bisphosphonate were identified as clinical risk factors on logistic regress…

expand abstract